The violation letters that started last September and continue this year might alter how brands craft DTC advertising. FDA is using a “totality of the evidence” standard to decide if an ad is in violation. That means they are now interpreting individual statements and creative elements together. While each statement might be true, FDA is […]
Direct-to-consumer (DTC) advertising once again took center stage during the Super Bowl. This year, four commercials aired that were directly related to prescription drugs or diagnostic testing—an increasing trend as pharmaceutical companies seek to make big, cultural-impact moments out of major live events. Historically, drug manufacturers have not heavily invested in Super Bowl advertising. That […]
AI is transforming healthcare engagement at unprecedented speed. Here's what most organizations are missing: automation without cultural intelligence creates irrelevance, inequity, and missed opportunity. With over 40% of Americans identifying as multicultural, our groundbreaking white paper reveals how the convergence of AI and cultural intelligence is reshaping patient engagement and why brands that master this intersection will own the future of […]
The FDA 9/9 letters reshaped DTC advertising. Three months later the real impact is emerging, from ad pauses to pushback on net impression claims. On September 9 the FDA issued 27 untitled letters to pharma companies over allegedly misleading television ads. We reviewed what has actually happened to the DTC efforts of those cited brands. […]
